Antihypertensive effects of selective prostaglandin E₂ receptor subtype 1 targeting
J. Clin. Invest. 117:9 doi:10.1172/JCI29838 [Go to this article.]

Figure 4
Effect of i. v. infusion of EP1/EP3 receptor agonists on MAP in EP1^–/– and EP1^+/+ mice.

(A) Temporal course showing reduced pressor effects of the mixed EP1/EP3 agonist 17-phenyltrinor PGE₂ (20 μg/kg i.v. bolus) in EP1^–/– (n = 5) versus EP1^+/+ (n = 3) mice. P < 0.0001, repeated-measures 2-way ANOVA. (B) Increase in peak MAP (at about 40–70 s) following 17-phenyltrinor PGE₂ (20 μg/kg i.v. bolus) was significantly less in EP1^–/– than in EP1^+/+ mice. ****P < 0.0001. (C) Identical peak pressor response to the pure EP3 agonist MB28767 in EP1^–/– (n = 3) and EP1^+/+ (n = 4) mice. (D) The peak pressor response to sulprostone (Sulp), another EP1/EP3 agonist, was reduced in EP1^–/– mice. ***P < 0.001. (E) Pretreatment of mice with the EP1-selective agonist SC51322 (n = 5) significantly reduced the peak pressor response to sulprostone. *P < 0.05.